IONS - Company ID 0000874015
The table below shows IONIS PHARMACEUTICALS INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Revenue | $246.09M | $203.33M | $156.72M | $452.05M | $131.61M | $226.58M |
| Cost of revenue | $2.98M | - | $2.34M | $4.15M | $1.46M | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
IONIS PHARMACEUTICALS INC reported annual revenue of $943.71M for fiscal year 2025. That is up 33.8% from $705.14M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $346.62M (FY 2016) to $943.71M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $150.36M |
| - |
| $96.81M |
| $90.62M |
| $76.25M |
| - |
| Operating income | -$117.42M | -$214.46M | -$160.18M | $139.82M | -$146.86M | -$110.82M |
| Income tax | $218.00K | - | $213.00K | -$20.00K | $116.00K | - |
| Net income | -$92.53M | -$229.39M | -$128.61M | $123.55M | -$146.94M | -$104.35M |
| EPS (diluted) | -$0.56 | -$1.41 | -$0.80 | $0.70 | -$0.93 | -$0.66 |